Calidi Biotherapeutics (CLDI) risk factors
Item 1A of every Calidi Biotherapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks4 new1 dropped9 reworded
Calidi Biotherapeutics faces severe going concern doubts with only $5.6 million in cash as of December 31, 2025. The company highlights new regulatory risks for its RedTail platform and dependence on ProBio in China for manufacturing the CAL1 oncolytic vaccinia virus strain.
Filed Mar 27, 2026 - FY2024 10-K risk factors69 risks
Calidi Biotherapeutics faces substantial going concern doubt due to recurring losses and no product revenue since inception. Development focuses on novel allogeneic stem cell and oncolytic virus candidates, requiring significant capital. Operations carry high regulatory, clinical trial, and manufacturing risks.
Filed Mar 31, 2025